AstraZeneca Forms Epigenetic Respiratory Drug Pact
By

By
AstraZeneca has formed a research pact for to advance epigentics for developing drugs to treat respiratory diseases with three UK-based research organizations. The partnership brings together AstraZeneca, Asthma UK, the…

Avara Acquires AstraZeneca UK Manufacturing Facility
By

By
Avara Pharmaceutical Services, Inc., a contract provider of bulk drug formulation and manufacturing as well as primary and secondary packaging for solid dose drugs, has agreed to acquire AstraZeneca’s manufacturing…

AstraZeneca Completes Divestment of Anesthetics Medicines to Aspen
By

By
AstraZeneca has completed its previously announced commercialization agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anesthetics portfolio outside the US. The closing…

BioCorRx Forms Subsidiary For Abuse-Deterrent Drug Development
By

By
BioCorRx Inc., an addiction-treatment company and developer of the BioCorRx Recovery Program, a medication-assisted treatment program, has formed a new subsidiary, BioCorRx Pharmaceuticals, in conjunction with the company’s development, commercialization…

Bayer, Monsanto Renew Talks for Possible $67 Billion Merger
By

By
In what would be its first large-scale acquisition as a pure-play life-sciences company, Bayer has confirmed that it is in “advanced negotiations” with the agrochemical and seed company, Monsanto, concerning…

Novo Nordisk CEO To Step Down; Successor Named
By

By
Novo Nordisk has announced that Lars Rebien Sørensen, president and chief executive officer (CEO), will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently executive vice…

Sunovion to Acquire Cynapsus Therapeutics
By

By
Sunovion Pharmaceuticals, a biopharmaceutical company headquartered in Marlborough, Massachusetts, has agreed to acquire Cynapsus Therapeutics, a Toronto-based specialty central nervous system pharmaceutical company focused on Parkinson’s disease, for $40.50 per…

Amgen Acquires Bispecific Antibody from BI
By

By
Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836909 (AMG 420), a bispecific T cell engager (BiTE) that targets B-cell maturation antigen (BCMA), a potential…

FDA OKs Sandoz’s Biosimilar to Enbrel
By

By
The US Food and Drug Administration (FDA) has approved Sandoz’s Erelzi (etanercept-szzs), a biosimilar of Enbrel (etanercept), for all indications included in the reference product label, including rheumatoid arthritis (RA),…

Dalton Completes Expansion Of Sterile Filling And API Facility
By

By
Dalton Pharma Services, a Toronto-based pharmaceutical services provider, has completed a $5-million expansion in sterile filling and active pharmaceutical ingredient (API) manufacturing at its cGMP facility in Toronto. The project…